The C-Suite: Sam Hupert, Pro Medicus CEO

Pro Medicus has flagged that FY 25 was an unprecedented year in terms of converting opportunities into sales, but says the opportunity pipeline remains strong. The medical imaging software company posted a record FY25 for new contract wins, pushing net profit up nearly 40%. Revenue growth was also strong, supported by it’s North American Segment. Pro Medicus will pay a fully franked final dividend of $0.30 a share. For more on the stellar numbers, have a listen to Pro Medicus CEO Sam Hupert.